Plan destroys biopharma innovation.
Miruna Sasu, Ph.D, President and CEO of COTA, Inc. May 2 2023 WILL THE INFLATION REDUCTION ACT STIFLE PHARMA INNOVATION? https://www.pharmalive.com/will-the-inflation-reduction-act-stifle-pharma-innovation/
While lower drug prices are a victory for patients, the legislation’s specific mechanisms for controlling costs could have dire unanticipated consequences for pharmaceutical innovation. Pharma companies looking to compensate for lower sales revenues may turn to trimming down their biggest cost centers — drug discovery and clinical trials — as well as any budget dedicated to improving efficiencies in their business. The result could be fewer new drugs, less innovation, and reduced access to breakthrough therapies, particularly for populations that already experience health equity barriers. To maintain the pace of innovation and ensure equitable access to new therapies over the coming decades, pharma companies will need to embrace new data-driven strategies and partnerships that bolster the drug discovery pipeline even in the face of financial uncertainty. Dozens of new therapies are approved every year in the United States, thanks to significant advances in clinical knowledge and the data science underpinning the innovation process. Over the past decade, global regulators 410 different drugs, approximately three-quarters of which are approved in the U.S. first. Pharma companies spend billions of dollars making these drugs for patients who often have exhausted all other options, and they must be careful about selecting which molecules to pursue through the expensive, complex, and time-consuming development process. Currently, pharma companies tend to enjoy once these therapies make it to market — and just like every other business, they would like to retain as much of their revenues as possible. Giving Medicare the power to negotiate drug prices may cut into these margins, resulting in pharmaceutical companies reducing the number of molecules they invest in.